The authors assessed the impact of two cycles of preoperative chemotherapy (POCT) with intraarterial cisplatin (120 mg/m2) and continuous intravenous doxorubicin hydrochloride (Adriamycin; 20 mg/m2/day X 3 days) on the decision to perform a limb-sparing procedure (LSP) or amputation in 22 patients with high-grade bone sarcomas of the extremities. The tumor types were osteosarcoma (17), malignant fibrous histiocytoma (three), leiom yosarcoma (one), and malignant schwannoma (one). Surgical stages were IIA (three), IIB (17), and IIIB (two). The prechemotherapy surgical options chosen were 12 amputations (55% of patients) and ten LSPs (45%). The initial decisions to amputate were based on a combination of the following: improper biopsy (five cases), large tumors (ten) and those with neurovascular encroach-From the
ment (six), and pathological fracture (one). Following chemotherapy, 18 LSPs (81%) and four amputations (19%) were performed. Nine of 12 patients (75%) initially deemed unresectable were converted to LSP. The median tumor response (necrosis; range, 0%-100%) was 70%; ten of 22 specimens had necrosis > 95%. Median tumor necrosis for the patients treated by amputation and LSPs was 45% and 88%, respectively. Following surgery, all patients received four additional cycles of cisplatin and doxorubicin. The median follow-up period is 30 months; six patients have developed metastatic disease, with a median disease-free interval of 16.6 months. The rate of local tumor control is 95% (21 of 22 patients). The authors conclude that (I) two cycles of POCT significantly increase the percentage of patients with highgrade bone sarcomas of the extremities who can be safely treated with a LSP, (2) a response to POCT has a strong influence on the surgical decisionmaking process, and (3) primary amputations are not recommended before a trial of POCT.
Postoperative adjuvant chemotherapy, in conjunction with surgery, has altered the outcome of patients with osteosarcomas. I A I I . I3,21 Elimination of systemic micrometastases appears t o be an important mechanism in the success of this form of therapy.
Two recent developments in management of bone tumors have been preoperative (neoadjuvant) chemotherapy and shorter overall lengths of adjuvant treatment.3,7.2' Preoperative chemotherapy (POCT) was first administered in the early days of limb-sparing surgery, during the mid-l970s, when the waiting period for a custom-made prosthesis ranged from two to three month^.^.'^.'^ Surgeons learned that POCT could reduce tumor size, cause tumor necrosis, and allow in vivo sensitivity testing. In addition, the role of POCT in conversion of unresectable tumors to those amenable to limb-salvage procedures was This study had two primary objectives: (1) to evaluate the impact of a short course (two cycles) of POCT on the surgical decision to perform a limb-sparing procedure (LSP) versus amputation, and (2) to evaluate the impact of a short duration (six cycles) of adjuvant chemotherapy on relapse-free and overall patient survival. This report describes the impact of POCT on the choice of surgical procedure; a subsequent report (awaiting longer follow-up intervals) will address the latter question. also investigated.3,4.6. IO, I5.16, 20, 21 MATERIALS AND METHODS Twenty-two patients with high-grade sarcomas of the extremities, including the shoulder and pelvis, participated in the study. There were I I males and I 1 females. The median age was 19.5 years (range, seven to 69 years). The histogenic diagnoses were osteosarcoma ( 17), malignant fibrous histiocytoma (3), leiomyosarcoma ( I ) , and malignant schwannoma ( I). The surgical stages (Musculoskeletal Tumor Society) were IIA (3), IIB ( I7), and IIIB (2). Staging studies to determine resectability included bone scans, plain roentgenographs, biplane arteriograms, computed tomography (CT) and/or magnetic resonance imaging (MRI) of the extremity, and chest CT.
STUDY DESIGN AND TREATMENT REGIMEN
Preoperative chemotherapy consisted of two cycles of intraarterial cisplatin (DDP) over four hours and continuous intravenous doxorubicin hydrochloride (Adriamycin [ADR]; dosage, DDP = 120 mg/m2 and ADR = 120 mg/m2.day-' X 3 days). Postoperatively, four cycles of DDP and ADR were given intravenously. The regimens were not altered on the basis of histologic tumor response (necrosis). Before POCT and after completion of the initial staging studies, a preliminary surgical decision (amputation or LSP) was recorded for each patient. Following POCT, all tumors were restaged, and a second, and final, surgical decision was made based upon the same criteria that had been used for the preliminary decision.
ANGIOGRAPHIC TECHNIQUE
Intravenous prehydration was started eight hours before cisplatinum therapy. Catheterization, with 5 French in adults and 4 French in children, was done via the femoral route using the standard Seldinger te~hnique.'~ Catheters were placed in the major vessels of the extremities: the common femoral, subclavian, and iliac arteries for distal femoral, proximal humeral, and pelvic tumors respectively. The superficial femoral artery was utilized for proximal tibia1 tumors. Selective catheterization was not performed. An arteriogram was performed and necessary adjustments of the catheter were made. The catheter was then attached to an arterial infusion pump, and the patient was adequately heparinized to prolong partial thromboplastin time to 1.5 to two times the normal. Mannitol (12.5 g) was given intravenously 15 minutes before cisplatin.
SURGICAL CONSIDERATIONS
The decision to proceed with a limb-sparing procedure was based on six key criteria: ( I ) The major neurovascular bundle should be free of tumor.
(2) Wide resection with a normal cuff of tissue in all directions should be possible. (3) En b/oc removal of potential sites of contamination, including biopsy sites, must be feasible. (4) Bone must be resectable 5 cm to 6 cm beyond the level indicated by preoperative imaging studies. (5) The adjacent joint and capsule must be resectable (distal femoral tumors were treated by an intraarticular procedure, whereas all proximal humeral resections were extraarticular). (6) Adequate muscle must be present for both motor power and coverage of the prosthetic implant.
The contraindications to limb-sparing resection used in this protocol were as follows: ( I ) major neurovascular involvement, (2) inappropriate biopsy sites with extensive soft-tissue contamination, (3) pathologic fracture, (4) large tumor size or absence of adequate muscle groups to allow a functional extremity, and (5) local infection. These contraindications were recorded for each pa- (Table I) . Immature skeletal age was not considered a contraindication.
PATHOLOGIC EVALUATION
The gross specimen was evaluated to determine the final surgical margin. Tumor necrosis was determined by the grid method.6 The percent tumor necrosis was recorded. "Good" and "poor" respondents were defined as greater than and less than 90% tumor necrosis respectively.
ANALYS~S
There were four possible options with respect to the preliminary and final surgical decision: LSPto-LSP. LSP-to-amputation, amputation-to-amputation. and amputation-to-LSP. The relationship of the initial and final surgical decisions were evaluated and compared to the degree of tumor necrosis and to the various surgical groups. Rates of local recurrence and disease-free survival were determined.
RESULTS

TYPE OF SURGICAL PROCEDURES
Initial sirrgical decision (Table 1) . Before POCT, 12 amputations and ten LSPs were chosen, representing a 45% limb-sparing rate. The initial decisions to perform amputation were based on one or a combination of the following considerations: poor biopsy with resultant contamination ( 5 patients), a large tumor( lOpatients),alargetumorwith neurovascular encroachment in which there was deemed no safe margin (7 patients). and pathologic fracture ( 1 patient).
Definitive siirgical decision. The definitive procedures performed following POCT were 18 LSPs and four amputations, representing an 8 1% limb-sparing rate. The types of procedures performed are presented in Table 2 .
Relationship of pre-versus post-POCT decision (Fig. 1) . Nine of 12 patients (75%) initially deemed unresectable were converted to a limb-sparing procedure; the remaining three patients received amputations. Nine of ten patients deemed initially resectable received a LSP: the remaining patient had local tumor progression with a secondary fracture and required a high above-knee amputation.
Relationship of rype yfsstrrgery lo tumor necrosis (Table 1) . All procedures accomplished a wide excision. The overall median necrosis was 70% (range, 0-100%). Ten of the 22 patients had greater than 95% necrosis. There was no difference in necrosis rate between the osteosarcoma ( 17) and nonosteosarcoma patients (5). The median necrosis for the patients treated by LSP and amputation were 88% and 45%, respectively. The median necrosis of the LSP-to-LSP (9 patients) and the amputation-to-LSP (9 patients) groups was 75% and 95% respectively. All specimen of these patients was 45%. Four of the five osteosarcoma patients had less than 90% necrosis. There has been one relapse among the six good respondents and two relapses among the nine poor respondents with osteosarcoma.
Overall local tumor control was 95% (21 patients). One patient developed a local recurrence following a limb-sparing procedure for a Stage IIB proximal femoral sarcoma and required a secondary hemipelvectomy. The primary specimen showed 95% tumor necrosis.
COMPLICATIONS
Deep muscle (myocutaneous) necrosis occurred in two patients. Neither required surgical debridement. Two patients developed arterial thrombosis (one before surgery and one intraoperatively); both required embolectomies. One patient developed an infection secondary to an infected subclavian line following a distal femoral prosthetic replacement. necessitating an above-knee amputation. 
DISCUSSION
The primary purpose of this prospective study was to determine the impact ofpreoperative chemotherapy on the choice of surgical procedure. as measured by the number of limb-sparing procedures versus amputations performed.
Clinical Orthopaedics and Related Research
The criteria of patient selection for LSP are based upon careful evaluation of clinical and radiographic parameters. In this study the initial (i.e., before POCT) surgical decision was LSP for 45% of the 22 patients. This percentage in itself is higher than that reported in studies that have involved postoperative adjuvant therapy alone; it reflects, in part, the authors' positive institutional experience with LSP. Following POCT, the LSP rate rose to 8 1 %. Nine of 12 patients who initially were judged to need an amputation were converted to a LSP. Only one patient became ineligible for limb sparing during POCT because of tumor progression.
The major preoperative factors necessitating an amputation were a poorly performed biopsy with significant local contamination of the soft tissue, adjacent joint or (both), and proximity of tumor to the neurovascular bundle. Tumor size in itself is usually not a contraindication; it affects the choice of surgery only in the sense that larger tumors tend to displace the major vessels or require a large amount of muscle to be resected and thereby reduce the function ofthe extremity. The neurovascular structures were displaced in some of our patients; however, they were not involved or infiltrated by tumor. Thus, a good response safely permits the widening of the margin along the vessels, either by shrinking the tumor or by destroying presumed local micrometastatic disease in the reactive zone of the tumor.
This study showed that the tumor necrosis of LSP patients was almost double that of patients who received amputations (88% versus 45% respectively). Interestingly, the amputation-to-LSP patients also had a greater necrosis (95% versus 75%) than did the initial LSP patients, although both groups had a higher rate than the patients who required amputation. The same degree of tumor necrosis was observed for both osteosarcoma and tumors other than osteosarcoma.
Almost all patients treated by a LSP had a tumor necrosis of greater than 50%, whereas those undergoing amputation had less than 50% response rate. Thus LSP can be performed safely if tumor necrosis is greater than 50%. This is different than the often quoted 90%, which relates to the reported improved likelihood of survival rather than to increased local tumor control. The authors recommend reserving amputation for those patients who do not respond clinically to POCT. Most patients, they noted, with greater than 60% tumor necrosis have a successful LSP. The low local failure rate of 5% observed in the current study indicates that a short course of POCT is effective in eradicating microscopic tumor nodules which, if left untreated, would lead to the development of a local recurrence (Fig. 2) .
Unfortunately, attempts to ascertain tumor necrosis before surgery have been unsuccessful. Preoperative biopsies are fraught with the danger of unrepresentative sampling errors. Preoperative scanning studies, if reli- . 2 . Schematic demonstrating the postulated regional tumor effect of intraarterial chemotherapy on presumed local microscopic disease and pulmonary micrometastases. The increased arterial concentration (large arrow) represents increased drug concentration to the local/regional tumor area. which may eradicate local skip lesions as well as the major tumor, thus permitting a safe local procedure to be performed. Following POCT there is marked rimming (arrows) of the extraosseous component, which indicates a good tumor response, even though the size did not significantly decrease. This patient initially was considered for amputation but was treated with a limb-sparing procedure instead. The gross specimen showed >90% tumor necrosis. able and reproducible, would help resolve this dilemma; however, the value and reliability of radiographic signs are far from settled. Data from the M.D. Anderson g r o~p '~-'~ suggest that angiograms may provide helpful information; however, these authors recommend using other studies and clinical criteria as we11.7.9.'4*17-'9 Plain roentgen rays and CT indicators of response include an increase in calcification, a decrease in, and better, definition of the soft-tissue component, and remodeling of the cortex (Figs. 3 and 4) .
Angiographic signs of necrosis include a reduction in vascular blush and possibly in tumor Some authors have reported that the correlation of CT and plain film with necrosis found at pathology is poorer than the correlation of angiography and histologic findings with necrosis. Other authors have incorporated a combination of clinical indica-tors such as a reduction of pain, size, temperature, and range of motion into their definition of r e s p o n~e .~-'~ The authors were unable to place full confidence in any single modality; however, in most cases, the combination of clinical and radiologic studies gave a good, although not completely quantifiable, assessment of the expected tumor response.
The authors' data suggest that one can probably convert an amputation to a LSP provided that there is no obvious tumor progression and radiographic studies indicate some regression (e.g., decreased vascularity and increased rimming seen on CT, plain roentgenography, or MR; Figs. 3-5). Such a decision was made for 75% of the patients in this study, who had initially been designated for treatment by amputation. The authors do not recommend excluding any patient from a trial of POCT, although an infected biopsy Clinical Orthopaedics and Related Research site (rare) or gross displaced fracture (unusual) may require a primary amputation. Pathologic fracture was a contraindication for LSP in this study. In selected cases where healing occurs following POCT, it may, however, be possible to attempt resection. This would have to be a subjective decision taken by a surgeon and based on experience.
In summary, this study suggests the following: (1) A short course (2 cycles) of POCT is safe and permits a significant amputation-to-LSP conversion. (2) Tumor necrosis of 50% or greater correlates with successful LSP. ( 3 ) No single preoperative indicator can reliably predict tumor response. Both clinical response and combined imaging data are required. (4) Most patients with high-grade bone sarcomas deserve a trial of POCT in an effort to replace amputation with LSP. (5) The impact of the route of administration and increase in number and intensity of courses of POCT on surgical decision-making requires further investigation. I .
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